Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses.

ABSTRACT:

Background

Circulating tumour DNA (ctDNA) has been established as a promising (prognostic) biomarker with the potential to personalise treatment in cancer patients. The objective of this systematic review is to provide an overview of the current literature and the future perspectives of ctDNA in non-metastatic rectal cancer.

Methods

A comprehensive search for studies published prior to the 4^th of October 2022 was conducted in Embase, Medline, Cochrane, Google scholar, and Web of Science. Only peer-reviewed original articles and ongoing clinical trials investigating the association between ctDNA and oncological outcomes in non-metastatic rectal cancer patients were included. Meta-analyses were performed to pool hazard ratios (HR) for recurrence-free survival (RFS).

SUBMITTER: van Rees JM 

PROVIDER: S-EPMC9922989 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature